<DOC>
	<DOCNO>NCT02489214</DOCNO>
	<brief_summary>This open-label , one-center , noncomparative , two-stage phase 1B trial assess donafenib advance gastric cancer .</brief_summary>
	<brief_title>Donafenib Monotherapy Previously Treated Metastatic Gastric Cancer</brief_title>
	<detailed_description>This open-label , one-center , noncomparative , two-stage phase 1B trial assess tyrosine kinase inhibitor donafenib tosilate tablet ( 400 mg/d,200mg bid ) patient advance , inoperable gastric cancer progress chemotherapy . The primary endpoint safety.The secondary endpoint tumor response progression-free survival time .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>All patient provide write , informed consent . Have histological cytological documentation gastric adenocarcinoma ; Have receive currently approve standard therapy disease progression within 3 month last administration last standard therapy stop standard therapy unacceptable toxic effect . Standard therapy include many follow licensed : fluoropyrimidine , oxaliplatin , irinotecan , paclitaxel , docetaxel ; trastuzumab patient Her2 positive tumour ; Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; Life expectancy least 3 month ; Have adequate bonemarrow , liver , renal function start trial . Prothrombin time international normalized ratio≤1.5； Patients brain metastasis . Patients receive cytotoxic chemotherapy , immunotherapy hormonal therapy , radiotherapy site measurable evaluable disease within previous 4 week . Patients evidence clinically active interstitial lung disease abnormal blood result predefined criterion ( serum bilirubin &gt; 1.5 time upper limit reference range , aspartate alanine aminotransferase &gt; 2.5 time upper limit normal demonstrable liver disease ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>donafenib</keyword>
</DOC>